In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations | Zendy

Natalie S. Nunnally | Zendy; Kizee A. Etienne | Zendy; David Angulo | Zendy; Shawn R. Lockhart | Zendy; Elizabeth L. Berkow | Zendy

Open Access

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Author(s) -

Natalie S. Nunnally,

Kizee A. Etienne,

David Angulo,

Shawn R. Lockhart,

Elizabeth L. Berkow

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01692-19

Subject(s) - anidulafungin , echinocandins , echinocandin , micafungin , candida glabrata , caspofungin , microbiology and biotechnology , broth microdilution , biology , in vitro , candida albicans , biochemistry , minimum inhibitory concentration , antifungal , antibiotics , amphotericin b , fluconazole

Ibrexafungerp is a first-in-class glucan synthase inhibitor.In vitro activity was determined for 89Candida glabrata isolates with molecularly identifiedFKS1 orFKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research